28209658|t|Relevance of ID3 - TCF3 - CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the NHL-BFM protocols
28209658|a|Mature B-cell Non-Hodgkin lymphoma is the most common subtype of Non-Hodgkin lymphoma in childhood and adolescence. B-cell Non-Hodgkin lymphoma are further classified into histological subtypes, with Burkitt lymphoma and Diffuse large B-cell lymphoma being the most common subgroups in pediatric patients. Translocations involving the MYC oncogene are known as relevant but not sufficient hit for Burkitt lymphoma pathogenesis. Recently published large-scale next-generation sequencing studies unveiled sets of additional recurrently mutated genes in samples of pediatric and adult B-cell Non-Hodgkin lymphoma patients. ID3, TCF3 and CCND3 are potential drivers of Burkitt-lymphomagenesis. In the present study frequency and clinical relevance of mutations in ID3, TCF3 and CCND3 were analyzed within a well-defined cohort of 84 uniformly diagnosed and treated pediatric B-cell Non-Hodgkin lymphoma patients of the Berlin-Frankfurt-Munster group (NHL-BFM). Mutation frequency was 78% (ID3), 13% (TCF3) and 36% (CCND3) in Burkitt lymphoma (including Burkitt leukemia). ID3 and CCND3 mutations were associated with more advanced stages of the disease in MYC rearrangement positive Burkitt lymphoma. In conclusion ID3 - TCF3 - CCND3 pathway genes are mutated in more than 88% of MYC - rearranged pediatric B-cell Non-Hodgkin lymphoma and the pathway may represent a highly relevant second hit of Burkitt lymphoma pathogenesis especially in children and adolescents.
28209658	0	9	Relevance	T080	C2347946
28209658	13	16	ID3	T028	C1415856
28209658	19	23	TCF3	T028	C1336596
28209658	26	31	CCND3	T028	C1413175
28209658	32	49	pathway mutations	T045	C0026882
28209658	53	62	pediatric	T080	C1521725
28209658	63	89	aggressive B-cell lymphoma	T191	C0079731
28209658	90	97	treated	T169	C1522326
28209658	115	132	NHL-BFM protocols	T061	C0040808
28209658	133	167	Mature B-cell Non-Hodgkin lymphoma	T191	C1334634
28209658	187	194	subtype	T185	C0449560
28209658	198	231	Non-Hodgkin lymphoma in childhood	T191	C0220612
28209658	236	247	adolescence	T079	C0001578
28209658	249	276	B-cell Non-Hodgkin lymphoma	T191	C0079731
28209658	305	326	histological subtypes	T185	C0449560
28209658	333	349	Burkitt lymphoma	T191	C0006413
28209658	354	383	Diffuse large B-cell lymphoma	T191	C0079744
28209658	406	415	subgroups	T185	C1515021
28209658	419	428	pediatric	T080	C1521725
28209658	429	437	patients	T101	C0030705
28209658	439	453	Translocations	T045	C1315049
28209658	468	480	MYC oncogene	T028	C0086661
28209658	530	546	Burkitt lymphoma	T191	C0006413
28209658	547	559	pathogenesis	T046	C0699748
28209658	580	626	large-scale next-generation sequencing studies	T059	C1294197
28209658	655	666	recurrently	T079	C2945760
28209658	667	680	mutated genes	T028	C0017337
28209658	684	691	samples	T167	C0370003
28209658	695	751	pediatric and adult B-cell Non-Hodgkin lymphoma patients	T101	C1516213
28209658	753	756	ID3	T028	C1415856
28209658	758	762	TCF3	T028	C1336596
28209658	767	772	CCND3	T028	C1413175
28209658	798	821	Burkitt-lymphomagenesis	T191	C0598766
28209658	844	853	frequency	T080	C3178846
28209658	858	876	clinical relevance	T080	C2347946
28209658	880	889	mutations	T045	C0026882
28209658	893	896	ID3	T028	C1415856
28209658	898	902	TCF3	T028	C1336596
28209658	907	912	CCND3	T028	C1413175
28209658	949	955	cohort	T098	C0599755
28209658	986	993	treated	T169	C1522326
28209658	994	1040	pediatric B-cell Non-Hodgkin lymphoma patients	T101	C1516213
28209658	1048	1078	Berlin-Frankfurt-Munster group	T185	C0008902
28209658	1080	1087	NHL-BFM	T185	C0008902
28209658	1090	1108	Mutation frequency	T080	C3178846
28209658	1118	1121	ID3	T028	C1415856
28209658	1129	1133	TCF3	T028	C1336596
28209658	1144	1149	CCND3	T028	C1413175
28209658	1154	1170	Burkitt lymphoma	T191	C0006413
28209658	1182	1198	Burkitt leukemia	T191	C0006413
28209658	1201	1204	ID3	T028	C1415856
28209658	1209	1214	CCND3	T028	C1413175
28209658	1215	1224	mutations	T045	C0026882
28209658	1230	1245	associated with	T080	C0332281
28209658	1260	1281	stages of the disease	T060	C0699749
28209658	1285	1288	MYC	T028	C0086661
28209658	1289	1328	rearrangement positive Burkitt lymphoma	T191	C0006413
28209658	1344	1347	ID3	T028	C1415856
28209658	1350	1354	TCF3	T028	C1336596
28209658	1357	1362	CCND3	T028	C1413175
28209658	1371	1376	genes	T028	C0017337
28209658	1409	1412	MYC	T028	C0086661
28209658	1415	1463	rearranged pediatric B-cell Non-Hodgkin lymphoma	T191	C0079731
28209658	1472	1479	pathway	T077	C1705987
28209658	1526	1542	Burkitt lymphoma	T191	C0006413
28209658	1543	1555	pathogenesis	T046	C0699748
28209658	1570	1578	children	T100	C0008059
28209658	1583	1594	adolescents	T100	C0205653